Overview
Portfolio
More
Santé Ventures
Austin, United States
Santé Ventures invests at the intersection of healthcare and technology, targeting early‑stage biotech, medtech, and healthtech companies that can improve patient outcomes and reduce costs. Leveraging deep industry exper...
Portfolio
3+
Employees
100+
Founded
2006
AUM
≈ $1.0B
Investment focus
Stages
Pre-Seed → Series A
Industries
BiotechnologyHealthcare Technology
Geographic scope
Global
Fund details
Funds
Fund II
Vintage 2011 • $130.0M
Fund IV
Vintage 2021 • $260.0M
Fund V
Vintage 2025 • $258.4M
Sources
Santé Ventures
Santé Ventures invests at the intersection of healthcare and technology, targeting early‑stage biotech, medtech, and healthtech companies that can improve patient outcomes and reduce costs. Leveraging deep industry expertise and data‑driven approaches, the firm backs innovative scientific and digital health solutions to drive both superior financial returns and meaningful health impact.
Portfolio
3+
Employees
100+
Founded
2006
AUM
≈ $1.0B
Funds
Fund II · Vintage 2011 • $130.0M
Fund IV · Vintage 2021 • $260.0M
Fund V · Vintage 2025 • $258.4M
Stages
Pre-Seed → Series A
Industries
BiotechnologyHealthcare Technology
Geographic scope
Global
Sources
Showing 3 of 3 matched portfolio companies
Clairity provides an FDA-authorized AI platform that assesses future breast cancer risk using existing screening mammograms. This technology analyzes image data to generate a validated, equitable five-year risk assessment for women. The platform transforms standard diagnostic imaging into a predictive tool for early detection and prevention planning.
Funding: $10.5M
Rough estimate of the amount of funding raised
Funding: $10.5M
Rough estimate of the amount of funding raised
CryOSA is developing a medical device that employs targeted airway pressure modulation to treat obstructive sleep apnea. This non-invasive approach enhances patient compliance and minimizes the risk of health complications associated with traditional CPAP therapy.
Funding: $40.3M
Rough estimate of the amount of funding raised
Solas BioVentures
Solas BioVentures
Funding: $40.3M
Rough estimate of the amount of funding raised
Solu Therapeutics develops a cytotoxicity-targeting chimera platform that links bifunctional small molecules to proprietary antibodies, enabling the selective elimination of disease-driving cells in oncology and autoimmune conditions. This approach addresses the challenge of targeting previously inaccessible cell surface proteins, enhancing therapeutic efficacy while minimizing safety risks.
20+
2K+Approximate amount of employees
Funding: $70.3M
Rough estimate of the amount of funding raised
Longwood FundSante Ventures
Longwood FundSante Ventures
Funding: $70.3M
Rough estimate of the amount of funding raised